The results of the DAPA-CKD trial have extended these findings to the broader population of patients with CKD (including participants with an eGFR 25–75 ml/min/1.73 m2), consisting approximately two-thirds of the population with and one third without T2D, and demonstrated that the SGLT2 inhibitor, dapagliflozin, conferred kidney protection in patients with CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.